Kenvue (NYSE:KVUE) Now Covered by Sanford C. Bernstein

Sanford C. Bernstein assumed coverage on shares of Kenvue (NYSE:KVUE) in a report published on Thursday, Marketbeat Ratings reports. The brokerage issued an underperform rating and a $18.00 price target on the stock.

Several other research firms have also weighed in on KVUE. UBS Group lifted their price target on Kenvue from $20.00 to $23.00 and gave the company a neutral rating in a research report on Tuesday, December 19th. William Blair assumed coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They issued a market perform rating on the stock. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research report on Friday, March 1st. They set a neutral rating and a $20.00 price target for the company. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an overweight rating for the company in a research note on Friday, February 9th. Finally, Royal Bank of Canada dropped their price target on Kenvue from $25.00 to $24.00 and set an outperform rating on the stock in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Hold and a consensus target price of $24.85.

Kenvue Stock Down 1.6 %

Shares of NYSE KVUE opened at $19.13 on Thursday. The firm has a fifty day simple moving average of $19.91 and a two-hundred day simple moving average of $20.19. Kenvue has a 12 month low of $17.82 and a 12 month high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. Kenvue’s revenue was down 2.7% on a year-over-year basis. Equities research analysts expect that Kenvue will post 1.17 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 annualized dividend and a dividend yield of 4.18%.

Hedge Funds Weigh In On Kenvue

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Empirical Finance LLC bought a new stake in shares of Kenvue in the third quarter worth approximately $336,000. UniSuper Management Pty Ltd bought a new stake in Kenvue in the 3rd quarter worth approximately $35,544,000. Howland Capital Management LLC purchased a new stake in Kenvue during the 3rd quarter valued at $7,764,000. Citizens Business Bank bought a new position in shares of Kenvue during the 3rd quarter valued at $2,507,000. Finally, Fifth Third Bancorp boosted its stake in shares of Kenvue by 35.3% in the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after buying an additional 72,435 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.